Item 8.01 Other Events
On March 11, 2019, Pfizer Inc. (the “Company”) completed a public offering of $500,000,000 aggregate principal amount of 2.800% Notes due 2022, $750,000,000 aggregate principal amount of 2.950% Notes due 2024, $1,750,000,000 aggregate principal amount of 3.450% Notes due 2029, $750,000,000 aggregate principal amount of 3.900% Notes due 2039 and $1,250,000,000 aggregate principal amount of 4.000% Notes due 2049 (together, the “Notes”).
The offering of the Notes was made pursuant to the Company’s shelf registration statement on FormS-3 (RegistrationNo. 333-223221) filed with the Securities and Exchange Commission on February 26, 2018.
The notes were issued pursuant to an indenture, dated as of September 7, 2018, between the Company and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented by the second supplemental indenture, dated as of March 11, 2019, between the Company and the Trustee (the “Second Supplemental Indenture”).
The Second Supplemental Indenture is filed herewith as Exhibit 4.2 to this Form8-K and is incorporated herein by reference.
In addition, in connection with the offering of the Notes, the Company is filing a legal opinion regarding the validity of the Notes, filed herewith as Exhibit 5.1 to this Form8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| | |
Exhibit No. | | Exhibit Description |
| |
4.1 | | Indenture, dated as of September 7, 2018 (incorporated by reference from the Company’s Current Report on Form8-K filed on September 7, 2018). |
| |
4.2 | | Second Supplemental Indenture, dated as of March 11, 2019. |
| |
4.3 | | Form of 2.800% Notes due 2022 (included in Exhibit 4.2). |
| |
4.4 | | Form of 2.950% Notes due 2024 (included in Exhibit 4.2). |
| |
4.5 | | Form of 3.450% Notes due 2029 (included in Exhibit 4.2). |
| |
4.6 | | Form of 3.900% Notes due 2039 (included in Exhibit 4.2). |
| |
4.7 | | Form of 4.000% Notes due 2049 (included in Exhibit 4.2). |
| |
5.1 | | Opinion of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company. |
| |
23.1 | | Consent of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company (included in Exhibit 5.1). |